{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:51:51Z","timestamp":1773661911776,"version":"3.50.1"},"reference-count":0,"publisher":"SMW Supporting Association","issue":"2122","license":[{"start":{"date-parts":[[2013,5,19]],"date-time":"2013-05-19T00:00:00Z","timestamp":1368921600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Swiss Med Wkly"],"abstract":"<jats:p>OBJECTIVE: Patients with recurrent triple-negative breast cancer (TNBC) currently  have no established treatment option other than chemotherapy. However, long-term  chemotherapy is often difficult due to adverse effects. A previous study documented  a 10%\u201330% response rate of progestins in oestrogen receptor\u2013negative breast  cancer. The aim of this study was to investigate the effect of  medroxyprogesterone\/megestrol acetate (MPA\/MA) in patients with recurrent TNBC.\n        METHODS: This retrospective observational analysis included 51 patients with recurrent  TNBC; 17 were treated with MPA\/MA and 34 underwent chemotherapy. The two groups  were matched at a 1:2 ratio according to age, metastatic sites, and salvage  treatment lines. Efficacy was compared using the \u03c72 and rank-sum  tests. Progression-free survival (PFS) was calculated using the Kaplan\u2013Meier method,  and the two groups were compared using the log-rank test.\n        RESULTS: The two groups were well balanced in terms of age,  disease-free survival, number of metastases, and salvage therapy lines. Clinical  benefit rates in the MPA\/MA and chemotherapy groups were 52.94% and 73.53%, respectively  (\u03c72 test, p = 0.208), and median  PFS was comparable between groups (log-rank test, p = 0.135). Median PFS of 1st\u20136th-line  salvage treatments was shorter in the MPA\/MA group than in the chemotherapy  group (log-rank test, p = 0.036), but  median PFS of \u22657th-line salvage treatments was comparable (log-rank test, p = 0.139). Eight patients  discontinued chemotherapy due to adverse effects, and one patient withdrew from  MPA treatment because of weight gain.\n        CONCLUSIONS: Progestins (MPA\/MA) are an alternative  treatment option for multi-treated  recurrent TNBC.<\/jats:p>","DOI":"10.4414\/smw.2013.13765","type":"journal-article","created":{"date-parts":[[2014,7,3]],"date-time":"2014-07-03T10:27:23Z","timestamp":1404383243000},"page":"w13765","source":"Crossref","is-referenced-by-count":1,"title":["Progestin  as an alternative treatment option for\u00a0multi-treated\u00a0recurrent triple-negative  breast cancer"],"prefix":"10.57187","volume":"143","author":[{"given":"Xiangying","family":"Meng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shikai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zefei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaohua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santai","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36756","published-online":{"date-parts":[[2013,5,19]]},"container-title":["Swiss Medical Weekly"],"original-title":[],"link":[{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/1696\/2272","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/1696\/2273","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/1696\/2272","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T04:31:04Z","timestamp":1755232264000},"score":1,"resource":{"primary":{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/view\/1696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,19]]},"references-count":0,"journal-issue":{"issue":"2122","published-online":{"date-parts":[[2013,5,20]]}},"URL":"https:\/\/doi.org\/10.4414\/smw.2013.13765","relation":{},"ISSN":["1424-3997"],"issn-type":[{"value":"1424-3997","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,19]]}}}